🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Secondary acute myeloid leukemia: time to turn the page haematologica.org/article/view/h… #AML #leusm

Brilliant news. Innovative patient centred blood cancer charities working cohesively to fund a trials infrastructure essential to improve transplant outcomes. Congratulations Anthony Nolan Cure Leukaemia NHS Blood+Transplant for your vision and commitment to patients

Blast-reduction strategies in MPN-AP/BP most commonly result in reversion to chronic phase MPN with significant residual disease burden. ow.ly/sg9A50QMWGa #myeloidneoplasia

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee ashpublications.org/blood/article/… #CMML #leusm

'We passionately believe that critical appraisal of trials is a core skill that all healthcare professionals should be able to perform.' We interview Drs Rich Buka and Pip Nicholson on their new podcast series discussing non-malignant haematology. ow.ly/Brpo50QQ72u

Respiratory failure in patients with hematologic malignancies This is really an amazing review in @BloodJournal on respiratory failure in patients with hematologic malignancies. A must read for ICU docs, pulm, ID, and hematologists. Gabriel Wardi tinyurl.com/y4ws6pt7

-Loss of #Dnmt3a increases self-renewal of JAK2V617F HSCs and mitigates their attrition upon chronic #pegIFNα Rx -A combination of pegIFNα and AZA can strongly decrease the JAK2-mut allele burden in MPN driven by JAK2V617F alone doi.org/10.1182/blood.… #MPNsm @BloodJournal

Delighted to share our Nature Protocols paper containing a detailed protocol for generating human bone marrow organoids. Amazing teamwork from the organoid crew MRC WIMM University of Oxford led by the unstoppable Abdullah Khan 🎉👇👇👏🏻

A giant leaves us nature.com/articles/d4158…

Thanks to The EBMT Mohamad Mohty Myriam labopin and the ALWP team for this analysis and Charlie Craddock CBE for inspiration in clinic!- kinetics of CR induction matters to post allo sct prognosis.

UHBMyeloid Dr francesca kinsella Manoj Raghavan Hayder Hussein @dr_peted Charlie Craddock CBE Our second regional myeloid update day with focus on MPN. Great talks and fantastic case studies from colleagues.

Brilliant work by my colleague Bernard Maybury. Most MYC/BCL6r lymphomas harbour a single-hit, reciprocal translocation t(3;8) between MYC and BCL6 (pseudo double-hit) and have better outcomes than t(3;8) negative double-hit cases. doi.org/10.1182/blood.…

Getting excited about seeing HaemSTAR 💙 #RAPIDO data at #BSH2024…2 hours to go

Why do AML patients with African ancestry have poor outcomes? Fascinating results indicate that genetics alter AML biology. Also, its Bailee Kain's first co-first author postdoc pub. Bailee Kain AK Eisfeld Nathan Salomonis and Elaine Mardis nature.com/articles/s4158…

Hugely important talk from Pramila Krishnamurthy on impact of ethnicity on patient outcome in AML. Emerging evidence of distinct disease biology and decreased transplant access contributing to worse outcomes. Vital area for research and action- supports launch of UK Myecare AML Registry.

Thanks Manoj Raghavan, Vidhya Murthy, Hayley UHB Research, Charlie Craddock CBE, Hayder Hussein for another great West Mids Myeloid Day on relapsed refractory #AML,high risk#MDS, and #CML. And cases from Richard Whitmill and Matt Kandathil The Royal Wolverhampton NHS Trust 🏥

DNMT3A, TET2, and ASXL1 mutations differentially shape the subsequent evolutionary trajectories of AML from diagnosis through relapse. ow.ly/rXck50VFJea #myeloidneoplasia